Effect of Pioglitazone on Production of Regulated upon Activation Normal T-cell Expressed and Secreted (RANTES) and IVF Outcomes in Infertile Women with Endometriosis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
This study was performed to investigate the effect of peroxisome proliferators activated receptor-γ (PPAR-γ) ligand, pioglitazone, on production of regulated upon activation normal T-cell expressed and secreted (RANTES) and in vitro fertilization (IVF) outcome in infertile patients with endometriosis. Sixty-four infertile patients with stage III or IV endometriosis undergoing IVF were randomly allocated to the study or the control group. The long protocol of GnRH agonist (GnRH-a) was used for controlled ovarian stimulation (COS) in all patients. Patients in the study group were treated with pioglitazone at a dose of 15 ㎎/day orally from the starting day of GnRH-a treatment to the day of hCG injection. Blood samples were drawn for serologic assay of RANTES on the first day of GnRH-a treatment and the day of hCG injection. There were no differences between the study and control groups in patient characteristics. There were also no differences between the two groups in COS duration, and the numbers of retrieved oocytes, fertilized oocytes and embryos transferred. The clinical pregnancy rate per cycle was higher in the study group, but this difference was not statistically significant. However, embryo implantation rate was significantly higher in the study group of 12.5% compared with 8.6% in the control group (P<0.05). The serum RANTES levels after pioglitazone treatment were significantly lower than those before pioglitazone treatmen in the study group (P<0.05). Our data suggest that pioglitazone treatment can suppress RANTES production and improve the embryo implantation rate in patients with endometriosis undergoing IVF.
Abstract
This study was performed to investigate the effect of peroxisome proliferators activated receptor-γ (PPAR-γ) ligand, pioglitazone, on production of regulated upon activation normal T-cell expressed and secreted (RANTES) and in vitro fertilization (IVF) outcome in infertile patients with endometriosis. Sixty-four infertile patients with stage III or IV endometriosis undergoing IVF were randomly allocated to the study or the control group. The long protocol of GnRH agonist (GnRH-a) was used for controlled ovarian stimulation (COS) in all patients. Patients in the study group were treated with pioglitazone at a dose of 15 ㎎/day orally from the starting day of GnRH-a treatment to the day of hCG injection. Blood samples were drawn for serologic assay of RANTES on the first day of GnRH-a treatment and the day of hCG injection. There were no differences between the study and control groups in patient characteristics. There were also no differences between the two groups in COS duration, and the numbers of retrieved oocytes, fertilized oocytes and embryos transferred. The clinical pregnancy rate per cycle was higher in the study group, but this difference was not statistically significant. However, embryo implantation rate was significantly higher in the study group of 12.5% compared with 8.6% in the control group (P<0.05). The serum RANTES levels after pioglitazone treatment were significantly lower than those before pioglitazone treatmen in the study group (P<0.05). Our data suggest that pioglitazone treatment can suppress RANTES production and improve the embryo implantation rate in patients with endometriosis undergoing IVF.
참고문헌 (24)
- Adams M, "Activators of peroxisome proliferator- activated receptor gamma have depot-specific effects on human preadipocyte differentiation", J Clin Invest, 100, pp.3149~3153 (1997)
- Appay V, "Rowland-Jones SL(2001)RANTES : a versatile and controversial chemokine", Trends Immunol, 22, pp.83~87 (2001)
- Arici A, "Interleukin-8 concentration in peritoneal fluid of patients with endometriosis and modulation of interleukin-8 expression in human mesothelial cells", Mol Hum Reprod, 2, pp.40~45 (1996)
- Arici A, "Monocyte chemotactic protein-1 concentration in peritoneal fluid of women with endometriosis and its modulation of expression in mesothelial cells", Fertil Steril, 67, pp.1065~1072 (1997)
- Azziz R, "Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial", J Clin Endocrinol Metab, 86, pp.1626~1632 (2001)
- Bedaiwy MA, "Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial", Hum Reprod, 17, pp.426~431 (2002)
- Conti P, "Chemokines in inflammatory states", Allergy Asthma Proc, 20, pp.205~208 (1999)
- Demir B, "Serum IL-6 level may have role in the pathophysiology of unexplained infertility", Am J Reprod Immunol, 62, pp.261~267 (2009)
- Hornung D, "Chemokine bioactivity of RANTES in endometriotic and normal endometrial stromal cells and peritoneal fluid", Mol Hum Reprod, 7, pp.163~168 (2001)
- Hornung D, "Nuclear peroxisome proliferatoractivated receptors alpha and gamma have opposing effects on monocyte chemotaxis in endometriosis", J Clin Endocrinol Metab, 86, pp.3108~3114 (2001)
- Khorram O, "Peritoneal fluid concentrations of the cytokine RANTES correlate with the severity of endometriosis", Am J Obstet Gynecol, 169, pp.1545~1549 (1993)
- Kim CH, "Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome", FERTILITY AND STERILITY, 94(1), pp.236~241 (2010), ELSEVIER SCIENCE INC
- Koninckx PR, "Endometriotic disease: the role of peritoneal fluid", Hum Reprod Update, 4, pp.741~751 (1999)
- Komar CM, "Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period", Endocrinol, 142, pp.4831~4838 (2001)
- Lago RM, "Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials", Lancet, 370, pp.1129~1136 (2007)
- Lebovic DI, "Immunobiology of endometriosis", Fertil Steril, 75, pp.1~10 (2001)
- Lenhard JM, "PPAR gamma", RXR as a molecular target for diabetes, 2001, pp.7, 249~258
- Missmer SA, "The epidemiology of endometriosis", Obstet Gynecol Clin North Am, 30, pp.1~19 (2003)
- Oral E, "The peritoneal environment in endometriosis", Hum Reprod Update, 2, pp.385~398 (1996)
- Pritts EA, "PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro", J Clin Endocrinol Metab, 87, pp.1841~1844 (2002)
- Seto-Young D, "Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production", J Clin Endocrinol Metab, 90, pp.6099~6105 (2005)
- Singh S, "Long-term risk of cardiovascular events with rosiglitazone: a metaanalysis", JAMA, 298, pp.1189~1195 (2007)
- Wu MY, "The role of cytokines in endometriosis", Am J Reprod Immunol, 49, pp.285~296 (2003)
- Yessoufou A, "Peroxisome proliferator-activated receptor alpha deficiency increases the risk of maternal abortion and neonatal mortality in murine pregnancy with or without diabetes mellitus: Modulation of T cell differentiation", Endocrinology, 147, pp.4410~4418 (2006)